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Several studies have demonstrated an association between prediabetes (preDM) 
and the incidence of Type II Diabetes Mellitus (T2DM). Many preventable factors can 
contribute to this association, namely behavioral and environmental conditions that lead 
to physiological changes and symptomology. Earlier identification of disease through 
combining common laboratory studies that demonstrate an elevated fasting glucose may 
be one mechanism to identify the vast majority of patients who are unaware of their 
preDM condition. Also, it has been widely demonstrated that T2DM can be effectively 
prevented or delayed with interventions geared towards weight management, physical 
activity, goal setting, and stress management. However, it is not entirely known whether 
education provided within a healthcare delivery system is effective in supporting patients 
to reach a 5% weight loss while reducing their overall incidence of T2DM disease. 
Furthermore, study is needed to evaluate such health interventions beyond effectiveness, 
to better identify effect and transferability through measuring the reach, adoption, and 
implementation. The objective of this dissertation was to determine: (a) the risk of T2DM 
among patients with confirmed and unconfirmed preDM relative to an at-risk group; (b) 
the association of a 5% weight loss with participation in the Intermountain Healthcare 
(IH) Diabetes Prevention Program (DPP); and, subsequently, (c) the reach, effectiveness, 
adoption, and implementation of the IH DPP intervention. The IH Enterprise Data 
Warehouse was utilized to evaluate these objectives. Patients with unconfirmed preDM 
 iv 
(HR 1.74; CI 1.59, 1.91; p<0.0001) and confirmed preDM (HR 2.77; CI 2.38, 3.23; 
p<0.0001) were more likely to develop T2DM when compared to at-risk patients. DPP 
participants were more likely to achieve a 5% weight loss within 6 months (OR 1.72; 
95% CI 1.29, 2.34; p<0.001) and less likely to have incident T2DM (OR 0.45; 95% CI 
0.24, 0.84; p=0.012) when compared to the no-DPP group. Lastly, DPP-based lifestyle 
interventions deployed within IH’s delivery system demonstrated moderate effectiveness 
in the short term, yet the proportion of patients (8%) who enrolled was low. Broad 
adoption across regions by providers and leadership revealed organizational buy-in (194 
providers at 53 clinics referred patients), while demonstrating that much of the clinical 
effect was seen when patients participated in interventions that were far less resource 
intensive (only 2.3 DPP counseling encounters on average). In conclusion, confirmed and 
unconfirmed preDM was associated with T2DM, however when patients participated in a 
DPP-based intervention, there was significant weight loss and reduction in T2DM 
incidence. Finally, the IH DPP demonstrated encouraging potential when evaluating 
organizational adoption and short-term effectiveness, yet may benefit from leveraging 
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Diabetes is a major cause of morbidity, disability, and mortality, affecting over 
27 million persons.1-3 In the United States, approximately 1.7 million individuals are 
newly diagnosed every year.3 The World Health Organization has predicted a global 
increase in diabetes prevalence by 39% between the years 2000 and 2030 and suggests 
that the number will increase to 366 million people by the year 2030.4 Diabetes can lead 
to heart disease and stroke, blindness, kidney disease, amputation, and eventually death 
when not properly managed.5 In 2010, it was the seventh leading cause of death in the 
United States.5  
In additional to the millions of diabetic individuals, there are 86 million persons 
identified with prediabetes (preDM) who are at increased risk for type II diabetes 
mellitus (T2DM).6 The majority of individuals with preDM are unaware that they have 
it, and a quarter of those with preDM will develop diabetes within 3 to 5 years of 
detection.7 
Two groups of patients have emerged in the recent literature with the highest 
susceptibility of being associated with incident disease: (a) at-risk patients defined by 
American Diabetes Association (ADA) criteria including body mass index (BMI) ≥25 
kg/m2 and one additional risk factor: high risk ethnicity, first degree relative with 




diabetes or polycystic ovary syndrome, or birth of a baby weighing >9 lbs), and (b) 
patients who meet the preDM criteria through laboratory testing of HbA1c (A1c 5.7-
6.49%) or fasting plasma glucose (FPG 100-125 mg/dL).2,3  
Of those with only risk factors for disease, gestational diabetes and polycystic 
ovarian syndrome tend to carry additional risk of T2DM as compared to other risk 
factors recognized by the ADA.8,9 In a systematic review of the literature, an A1c range 
of 5.7–6.49% had a 5-year risk of developing diabetes between 25–50% and a relative 
risk 20 times higher compared with an A1C of 5.0%.10 In addition, observational 
evidence suggests that there is an association between preDM and complications of 
diabetes such as early nephropathy, small fiber neuropathy, early retinopathy, and risk of 
macrovascular disease.11 Within a community-based study of adults without diabetes, 
preDM was a stronger predictor of subsequent cardiovascular events and incident 
diabetes diagnosis.12  
A third group, patients with preDM who are unaware of their condition,1,3 is 
emerging as a vital target population for identification and intervention. Patients with 
unidentified or unconfirmed preDM may be identified by pairing several laboratory 
studies that are routinely ordered in clinical practice: a fasting lipid panel accompanied 
by a chemistry panel on the same day that documents a glucose level between 100-125 
mg/dL. While studies have evaluated the incremental risk of T2DM for patients with 
confirmed preDM or risk factors for disease, there is little report on the clinical course 
for patients who are unaware of their condition and their risk trajectory for T2DM. 
Diabetes results from a combination of genetic predisposition, behavioral and 




many other subsequent chronic diseases.4 However, there is strong evidence that such 
modifiable risk factors such as bad health behaviors, nutrition, obesity, and physical 
inactivity are the main behavioral or environmental determinants of the disease.4 General 
consensus among practitioners is that to combat diabetes, we must first undergo 
measures to prevent it.  
Several prominent studies have demonstrated that strategies to support weight 
loss and weight loss maintenance are the key to preventing the development of diabetes 
in those at-risk for disease.13-18 More importantly, the Diabetes Prevention Program 
(DPP) Outcomes Study demonstrated that the prevention or delay of diabetes with 
lifestyle intervention or metformin can persist for over ten years.19 DPP strategies have 
been reproduced and modeled in many other countries and clinical settings, and with 
differing populations,14,17-23 yet much less evidence exists on pragmatic lifestyle 
interventions deployed within health systems for patients diagnosed with preDM.  
Studies have shown that DPP-based lifestyle interventions are efficacious, and 
furthermore, these interventions are readily accessible with the potential for substantial 
clinical and public health impact.18 However, to date, only a few health systems have 
deployed interventions aimed at weight loss and physical activity for prevention of 
T2DM.24,25 While studies have shown moderate levels of weight loss and clinical benefit 
from DPP-based strategies, the reach into target population tends to be meager, and there 
is little evidence regarding the organizational adoption or fidelity to the intervention as 
intended.26,27  
In early 2013, Intermountain Healthcare (IH) deployed a modified form of the 




with preDM, provide a mechanism for provider referral into the program and included 3 
different pathways for participation. The primary purpose of the DPP was to support 
patients in attaining a 5% weight loss within 6 months of enrollment shown to be most 
effective at reducing the incidence of T2DM.14 
Determination of T2DM risk for patients with confirmed and unconfirmed 
preDM relative to those at-risk for disease would be beneficial to provide clinical 
guidance to physicians on who should be referred for lifestyle interventions. 
Additionally, if the DPP was able to demonstrate sufficient reach into our at-risk 
population, achievement of a 5% weight loss and a reduction in the incidence of T2DM, 
wide organizational adoption, and overall implementation fidelity, then such a program 
could be translated across the care continuum while providing greater health and value to 
patients and the delivery system alike. 
This dissertation addressed the following specific aims: 
1. Determine the incidental risk of Type II diabetes mellitus among patients with 
confirmed and unconfirmed prediabetes relative to an at-risk group receiving 
care from primary care physicians over a 5-year period. 
2. Evaluate the short-term effectiveness of the Intermountain Healthcare 
Diabetes Prevention Program for patients with prediabetes deployed within 
primary care clinics. 
3. Evaluate the reach, effectiveness, adoption, and implementation of the 
Intermountain Healthcare Diabetes Prevention Program utilizing the RE-AIM 
framework among patients identified with prediabetes deployed within 
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INCIDENTAL RISK OF TYPE II DIABETES MELLITUS 
 





To determine the risk of type 2 diabetes (T2DM) diagnosis among patients with 
confirmed and unconfirmed prediabetes (preDM) relative to an at-risk group receiving 
care from primary care physicians over a 5-year period. 
Study Design 
Utilizing data from the Intermountain Healthcare (IH) Enterprise Data 
Warehouse (EDW) from 2006–2013, a retrospective analysis was performed using 
discrete survival analysis to estimate the time to diagnosis of T2DM among groups.  
Population Studied 
All adult patients who had at least one outpatient visit with a primary care 
physician (family medicine, internal medicine, or geriatric specialty) during 2006–2008 
at an IH clinic and subsequent visits through 2013 were included. Patients were further 
selected for the study if they met criteria for (a) at-risk for diabetes (BMI ≥ 25 kg/m2 and 
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one additional risk factor: high risk ethnicity, first degree relative with diabetes, elevated 
triglycerides or blood pressure, low HDL, diagnosis of gestational diabetes or polycystic 
ovarian syndrome, or birth of a baby weighing >9 lbs); or (b) confirmed preDM (HbA1c 
≥ 5.7–6.49% or fasting blood glucose 100–125 mg/dL); or (c) unconfirmed preDM 
(documented fasting lipid panel and glucose 100-125 mg/dL on the same day).  
Principal Findings 
Of the 33,388 patients who were eligible for study, 57.0% were considered at-
risk, 38.4% had unconfirmed preDM, and 4.6% had confirmed preDM. Average age was 
51.1 years and 45.9% were females. Those with unconfirmed and confirmed preDM 
tended to be Caucasian (88.0%; 89.6%; 81.2%, respectively) and a greater proportion 
were obese (66.0%; 67.0%; 52.14%, respectively) as compared to those at-risk for 
disease. Patients with unconfirmed and confirmed preDM tended to have more prevalent 
high blood pressure (31.1%; 35.2%; 30.4%, respectively) and depression (18.6%; 27.4%; 
17.4%, respectively) as compared to the at-risk group. Based on the discrete survival 
analyses, patients with unconfirmed preDM (HR 1.74; CI 1.59, 1.91; p<0.0001) and 
confirmed preDM (HR 2.77; CI 2.38, 3.23; p<0.0001) were more likely to develop 
T2DM when compared to at-risk patients.  
Conclusions 
Unconfirmed and confirmed preDM is strongly associated with the development 
of T2DM as compared to patients with only risk factors for disease. As IH transitions 
from the current episodic, volume-driven model of disease management to one that 
rewards value and promotes population health through prevention and wellness, these 




the health needs of our target population while coordinating services to improve the 
health of that population. 
Introduction 
Type 2 diabetes mellitus (T2DM) is one of the most costly diseases due to the 
size of the population at risk and the fact that diabetes is a risk factor for almost all other 
chronic diseases.1,2 The World Health Organization has predicted a global increase in 
diabetes prevalence by 39% between the years 2000 and 2030, representing a global 
increase to 366 million people by the year 2030.3 In additional to the millions of 
individuals with T2DM, there are an estimated 86 million Americans identified with 
prediabetes (preDM) who are at increased risk for the development of T2DM over time, 
yet only 14% of individuals are aware of their condition.4  
Two groups of patients have emerged in the recent literature with the highest 
susceptibility of being associated with incident diabetes: (a) at-risk patients defined by 
American Diabetes Association (ADA) criteria including body mass index (BMI) ≥25 
kg/m2 and one additional risk factor: high risk ethnicity, first degree relative with 
diabetes, elevated triglycerides or blood pressure, low HDL, diagnosis of gestational 
diabetes or polycystic ovary syndrome, or birth of a baby weighing >9 lbs); and (b) 
patients who meet the preDM criteria through laboratory testing of HbA1c (A1c 5.7-
6.49%) or fasting plasma glucose (FPG 100-125 mg/dL).4-6  
When evaluating the effect of individual risk-factors for T2DM, patients with 
gestational diabetes and polycystic ovary syndrome have the highest rates of newly 
diagnosed diabetes.7 A handful of studies have shown that a quarter of those with 




evidence suggests that there is an association between confirmed preDM and 
complications of diabetes such as early nephropathy, small fiber neuropathy, early 
retinopathy, and risk of macrovascular disease.9 Beginning in the early 1990s, several 
prominent studies have demonstrated that strategies to support weight loss and weight 
loss maintenance are the key to preventing development of T2DM in the prediabetic or 
those at-risk for disease.10-15  
Patients who have undiagnosed or unconfirmed preDM have also been identified 
as a vital target population, yet to date, there has been little data collected on how to 
identify this population and the trajectory of illness that a patient with unconfirmed 
preDM might face.16 As postulated by this study, unconfirmed preDM patients were 
identified by pairing laboratory studies that are routinely ordered in clinical practice: a 
fasting lipid panel accompanied by a chemistry panel on the same day that documents a 
glucose level between 100–125 mg/dL. Patients meeting this “unconfirmed” criteria may 
not have any evidence of preDM documented in their medical record since their provider 
was unaware of the condition and furthermore, these patients may not have been treated 
using evidence-based therapies such as metformin to impede disease progression. 
Nevertheless, these patients do in fact meet the ADA criteria for preDM and may have 
increased risk of developing T2DM in the future.  
While previous research provides an informative perspective on the health 
outcomes faced by patients with confirmed preDM and those with risk factors for 
disease, the clinical course among patients with unconfirmed preDM has yet to be 
determined. To address this gap in knowledge, the primary purpose of this paper is to 




unconfirmed prediabetes relative to an at-risk group receiving care from primary care 
physicians over a 5-year period.  
Methods 
A longitudinal, closed cohort design was utilized to determine the association of 
T2DM over time among three groups of patients considered at higher risk for disease. 
Study Subjects and Practice Attribution 
Subjects 
A source population of adult patients (≥18 years of age) who had at least one 
outpatient visit with a primary care physician (Family Medicine, Internal Medicine, or 
Geriatric specialty) during 2006–2008 and received continued treatment through 2013 
were identified in IH’s Enterprise Data Warehouse (EDW). Patients meeting source 
inclusion criteria were further delineated for study if they did not have a known death or 
prevalent T2DM. As defined in Table 2.1, patients were included for study if they met 
criteria for (a) at-risk for diabetes or (b) confirmed preDM or (c) unconfirmed preDM. 
This study was approved by the IH Institutional Review Board. 
Patient Attribution 
To adjust for practice variation, we attributed patients to a primary care provider 
and practice who provided the plurality of qualifying services (Current Procedural 
Terminology codes for outpatient office visit, preventive medicine visit, or wellness 
visit: 9920x, 9921x, 99385-87, 99395-97, G0101, G0402, G0438) in a given calendar 




Table 2.1. Definition of Study Groups 
Study group Definition 
  
At-risk for diabetes BMI ≥ 25 kg/m2 + one additional risk factor: 
 High risk ethnicity (Asian, African Americans, 
Hispanic, Native Americans) 
 1st degree relative with Diabetes 
 HDL <35 mg/dL 
 Triglycerides >250 mg/dL 
 Hypertension >140/90 mmHg 
 Gestational Diabetes diagnosis 
 Polycystic Ovary Syndrome diagnosis 
 Baby weighing >9lbs 
  
Unconfirmed prediabetes Chemistry Panel (with Glucose 100-125 mg/dL) on 
same day as Fasting Lipid Panel  
  
Confirmed prediabetes HbA1c 5.70-6.49%  
or..... 







As determined by clinical health characteristics, patients with differing levels of 
disease were compared to assess whether differences in patient demographics, social 
factors, as well as clinical and practice characteristics existed prior to diagnosis. Baseline 
demographics included age, sex, and race/ethnicity. Clinical characteristics for the study 
cohort included the proportion of patients with chronic conditions prior to study 
enrollment including: depression, coronary heart disease, congestive heart failure, atrial 
fibrillation, and high blood pressure. Criteria for chronic conditions are different for each 
condition; however, they are based on diagnosis codes and encounter data, and are 
approved by an internal expert committee of practicing providers (Table 2.2). Also 
included were the medication classes that were ordered (anti-hypertensive, atypical-
neuroleptics, metformin, and statins) as well as weight (kilograms) and body mass index 
class (underweight, normal, overweight, or obese) at baseline. Data on other potential 
confounders were collected at varying points in time when a patient touched the delivery 
system: the specialty type of primary care provider (Family Medicine, Internal Medicine, 
or Geriatrics) and panel size of practice. The geographical region where services were 
provided was also included. 
Study Endpoints 
Time to diagnosis of T2DM was the primary outcome of interest. T2DM was 
defined by the National Committee for Quality Assurance (NCQA) through the 
Healthcare Effectiveness Data and Information Set (HEDIS) specifications.17,18 These 




Table 2.2. Definitions of Chronic Conditions 
Chronic 
condition 
Diagnoses   
(ICD-9-CM)a Encounters (CPT)a Exclusions 
    
High blood 
pressure 
360.42,  362.11, 401, 401.0, 
401.1, 401.9, 402, 402.0, 
402.00, 402.01, 402.1, 402.10, 
402.11, 402.9, 402.90, 402.91, 
403, 403.0, 403.00, 403.1, 
403.10, 403.9, 403.90, 404, 
404.0, 404.00, 404.01, 404.1, 
404.10, 404.11, 404.90, 404.9, 
404.91, 405, 405.0, 405.01, 
405.09, 405.1, 405.11, 405.19, 
405.9, 405.91, 405.99, 437.2 
Outpatient visit with either:                                              
99201-05, 99211-15, 99241-
45, 99341-50, 99381-87, 
99391-97, 99401-04, 99411-
12, 99420, 99429, 99455-56 
No documentation
of renal transplant 
    
Atrial 
fibrillation 
427.31 Inpatient admission with 
either: 3734, 3726-28 
none 
    
Coronary 
artery disease 
410.xx, 411.0, 411.1, 411.81, 
411.89, 412.0, 413.0, 413.9, 
414.0, 414.01, 414.02, 414.03, 
414.04, 414.05, 414.06, 
414.07, 414.11, 414.80, 414.90  
none none 
    
Heart failure 398.91, 402.01, 402.11, 
402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 
404.93, 428.0, 428.1, 428.20, 
428.21, 428.22, 428.23, 
428.30, 428.31, 428.32, 
428.33, 428.40, 428.41, 
428.42, 428.43, 428.9 
none none 
    
Depression 296.2, 296.20, 296.21, 296.22, 
296.23, 296.24, 296.25, 
296.26, 296.3, 296.30, 296.31, 
296.32, 296.33, 296.34, 
296.35, 296.36,  296.82, 
296.90, 298, 298.0, 300.4, 
309.1, 309.28, 311 
Hospital admission or... none 
Emergency Department Visit 
or… 
Outpatient visit with either:                                              
99201-05, 99211-15, 99241-
45, 99341-50, 99381-87, 
99391-97, 99401-04, 99411-
12, 99420, 99429, 99455-56 
    
Note. ICD-9-CM: The International Classification of Diseases, Ninth Revision, Clinical Modification; 
CPT: Current Procedural Terminology 
 
a To be identified with a chronic condition, specifications require at least one CPT and ICD-9-CM code to 




diabetes (ICD-9 code: 250): (a) two outpatient encounters on different dates of service; 
(b) one acute inpatient encounter; (c) one emergency department visit; or (d) patients 
who were dispensed insulin or hypoglycemic/anti-hyperglycemics on an ambulatory 
basis. Other outcomes included the number who converted to T2DM. All outcomes were 
assessed thru December 31, 2013. For patients who were censored or did not develop 
T2DM disease, the last IH encounter was used as the censor date.  
Statistical Analysis 
Summary statistics were computed which included means, medians, standard 
deviations, and ranges to describe the study population characteristics. Continuous 
variables were compared between study groups using analysis of variance followed by 
adjustment for multiple comparisons using a Tukey pairwise analysis. Chi-square 
analysis was used to determine differences in proportions for categorical variables. 
Discrete survival analysis modeling was utilized to test the null hypothesis that 
time to T2DM diagnosis was no different among patients with differing levels of disease. 
Patients categorized as at-risk for diabetes were considered the referent group. Hazard 
ratios were generated after adjustment for static and time-varying variables including 
demographic, clinical characteristics, and practice variation that are well known to affect 
the risk of diabetes. Due to the intrinsically discrete intervals of interest for a provider, 
the time-to-event data were divided into intervals of 6-month increments and the model 
was further adjusted for the number of times a patient visited the delivery system. The 
interval of care (180 days) was selected because evidence-based guidelines suggest twice 
yearly follow up with a provider for patients at increased risk for T2DM.19 Nonadjusted 





The effect of any interaction between age and study group was also assessed. 
Patients were categorized into two age groups based on the screening recommendation 
from the American Diabetes Association4,6: (a) < 45 years and (b) ≥45 years. These age 
groupings, along with the study group, created an interaction term that could be studied 
to determine the impact on time to T2DM.  
For all analyses, a p-value ≤0.05 was considered statistically significant. All data 
were analyzed using Stata 12.0 (Stata Corp, College Station, TX). 
Results 
As documented in Figure 2.1, 631,174 patients who received at least one 
outpatient visit with a primary care physician (Family Medicine, Internal Medicine, 
Geriatric specialty) within the IH Delivery system during 2006–2008 were identified. Of 
these, 352,304 were excluded because they had no known increased risk for T2DM. An 
additional 213,138 patients were excluded because their age at time of study enrollment 
was <18 years of age. Another 31,894 patients were excluded because they had a known 
date of death during the study. Of the study population that remained, 8.76% (n=33,838) 
patients were identified as: at-risk (57.0%; n=19,288), unconfirmed preDM (38.4%; 
n=13,005) and those with confirmed preDM (4.6%; n=1,545). For patients within the at-
risk group, 100% had a body mass index ≥ 25 kg/m2; 37.4% were diagnosed with 
hypertension (blood pressure >140/90); 33.1% had an HDL <35mg/dL; 21.5% had 
triglycerides >250 mg/dL; 13.4% were of high-risk ethnicity; 2.9% had a baby weighing 
over >9lbs; 1.7% had a first degree relative with diabetes; 1.3% were diagnosed with 









could have multiple indications for risk, and thus the proportion among the group does 
not add up to 100%). 
Baseline demographic and clinical characteristics are summarized in Table 2.3. 
Over half (59.38%) of the unconfirmed preDM group were male compared to 51.01% 
and 48.87% in the at-risk and confirmed preDM group. Patients tended to be older in 
both the unconfirmed and confirmed preDM groups as compared to the at-risk group 
(54.1, 54.1, and 48.7 years, respectively). 
Patients with confirmed preDM tended to have more depression, coronary heart 
disease, congestive heart failure, atrial fibrillation, and high blood pressure (p<0.001) as 
compared to patients in the other groups. Similarly, patients with confirmed preDM 
tended to have more ordered medications at time of diagnosis (p<0.001) as compared to 
other study groups. Weight at baseline did not seem to differ clinically; however, the 
finding was statistically significant. Patients in the unconfirmed and confirmed preDM 
group tended to be categorized more commonly as obese rather than those at-risk 
(66.01%, 66.93%, and 52.14%; p<0.001). 
Actuarial risk for T2DM is shown in Figure 2.2, demonstrating an increasing 
separation between the study groups across the entire study period (p<0.0001). There 
was also a significant difference at 3- and 5-year intervals for risk of T2DM when 
comparing the study groups (p<0.001). Overall 9% (n=2,883) had converted to T2DM 
within 5 years, 20% (n=302) in the confirmed preDM group, 11% (n=1,391) in the 
unconfirmed group, and 6.0% (n=1,190) in the at-risk group. The average study follow-
up did not seem to differ clinically among the confirmed, unconfirmed and at-risk groups 




Table 2.3. Baseline Characteristics 
Variables 
At-risk for 
Diabetes                         
n= 19,288            
mean± SD or % 
Unconfirmed 
Prediabetes                         
n=13,005             
mean± SD or % 
Confirmed 
Prediabetes                         
n=1,545              
mean± SD or 
% p 
     
Demographics 
Age at Study Enrollment, yrs 48.67±15.28 54.09± 11.99 54.10± 13.02 <0.000 
Age categories, %       <0.000 
18-29 15.06 3.65 5.31  
30-39 17.03 9.43 9.71  
40-49 18.65 21.04 17.99  
50-59 21.84 32.11 31.00  
60-69 18.69 24.93 24.40  
≥ 70 8.73 8.84 11.59  
Sex, %       <0.000 
Male 51.01 59.38 48.87  
Female 48.99 40.62 51.13  
Race/ethnicity       <0.000 
White 81.17 87.92 89.58  
Asian 2.86 1.60 1.68  
Black 2.31 0.57 0.39  











Chronic conditions, %        
High blood pressure 37.40 31.13 35.15 0.0004 
Depression 17.36 18.6 27.38 <0.000 
Coronary heart disease 9.22 9.4 11.78 <0.000 
Congestive heart failure 3.64 2.99 5.24 <0.000 
Atrial fibrillation 3.02 2.01 3.50 <0.000 
Medication class, %        
Anti-hypertensive 28.31 26.91 27.83 <0.000 
Anti-neuroleptics 2.59 1.94 6.60 <0.000 
Metformin 1.17 1.96 3.56 <0.000 
Statin 15.09 24.94 26.08 <0.000 
Weight at baseline, kg 93.01±23.39 94.50±24.18 94.25±23.34 <0.000 
BMI class at baseline, %       <0.000 
Underweight 0.0 0.65 0.91  
Normal 0.0 8.96 10.49  
Overweight 47.86 24.38 21.68  
Obese 52.14 66.01 66.93  
Follow-up time, yrs 5.23 5.14 4.94 <0.000 






Figure 2.2. Kaplan-Meier Actuarial Survival Curve Showing Accumulated Diabetes 




significant. When a group of healthy patients (criteria: no known risk of T2DM; at least 
2 encounters to their provider during 2006–2008; no known death or prevalent T2DM) 
were included as the referent, there were no significant differences between that group 
and the at-risk group in terms of the incident risk of developing T2DM over time (Figure 
2.3). 
Utilizing discrete survival analyses adjusted for possible confounders, patients 
with unconfirmed preDM were 67% more likely to develop T2DM as compared to those 
at-risk (HR 1.67; CI 1.53, 1.83; p<0.0001). Patients with confirmed preDM had over a 
2.5-fold increase of incident T2DM as compared to at-risk patients (HR 2.73; CI 2.37, 
3.15; p<0.0001). Patients on metformin (HR 4.01; CI 3.37, 4.78; p<0.0001) and those 
with a diagnosis of high blood pressure at study enrollment (HR 1.16; CI 1.05, 1.27; 
p=0.002) tended to have significantly greater risk of developing T2DM while patients 
with depression showed a decreased risk of disease (HR 0.85; CI 0.77, 0.94; p=0.001). 
Patients with a BMI that was considered either overweight or obese were at higher risk 
for T2DM (p<0.0001). All multivariate results are documented in Table 2.4. Also, when 
assessing the interaction between age and study group, there was a significant association 
demonstrating a step-wise relationship in risk of developing T2DM with greater age and 
known preDM (Table 2.5.).  
Discussion 
Although a sizeable proportion of the study population did not develop incident 
disease over the 5-year study period, patients with confirmed and unconfirmed preDM 
showed a compelling association with risk of T2DM, even when adjusting for baseline 





Figure 2.3. Kaplan-Meier Actuarial Survival Curve Showing Accumulated Diabetes 
Diagnosis Rates over Time among Patients with Confirmed and 
Unconfirmed Prediabetes, Those At-Risk for Diabetes, Relative to a 




Table 2.4. Incidental Risk of Type II Diabetes Mellitus among Patients with Confirmed 
and Unconfirmed Prediabetes as Compared to Those At-Risk for Disease 
 Covariates 





mellitus Hazard ratio 95% CI p 
      
Demographics 
Study Group         
At-risk for Diabetes 19,288 1,190 ---- ---- ---- 
Unconfirmed prediabetes 13,005 1,391 1.67 1.53, 1.83 <0.000 
Confirmed prediabetes 1,545 302 2.73 2.37, 3.15 <0.000 
Age (years)       
18-29 3,462 47 ---- ---- ---- 
30-39 4,662 203 2.34 1.55, 3.52 <0.000 
40-49 6,612 413 3.07 2.07, 4.56 <0.000 
50-59 8,867 882 3.96 2.68, 5.85 <0.000 
60-69 7,223 921 3.92 2.65, 5.80 <0.000 
≥ 70 3,012 417 3.67 2.46, 5.48 <0.000 
Female sex 15,523 1,392 0.91 0.83, 0.98 0.018 
Race       
Caucasian 28,474 2,598 ---- ---- ---- 
Asian 786 64 2.24 1.74, 2.88 <0.000 
Black 525 32 1.23 0.85, 1.77 0.278 
Hispanic 841 8 0.84 0.38, 1.86 0.662 
Other 1,102 79 1.53 1.19, 1.98 0.001 
Unknown 2,110 102 1.11 0.89, 1.37 0.356 
Clinical Characteristics 
Chronic conditions        
Depression 6,190 646 0.85 0.77, 0.94 0.001 
Coronary heart disease 3,183 374 1.10 0.96, 1.25 0.164 
Congestive heart failure 1,173 142 0.91 0.74, 1.12 0.364 
Atrial fibrillation 899 82 0.73 0.57, 0.94 0.014 
High blood pressure 10,456 1,311 1.16 1.05, 1.27 0.002 
Medication class       
Anti-hypertension 8,617 993 1.04 0.95, 1.15 0.370 
Atypical-neuroleptics 854 85 0.86 0.68, 1.10 0.234 
Metformin 535 190 4.01 3.37, 4.78 <0.000 
Statin 6,556 746 0.96 0.87, 1.06 0.416 
BMI class at baseline       
Normal 2,573 106 ---- ---- ---- 
Underweight 175 13 2.53 1.36, 4.73 0.003 
Overweight 11,414 527 1.39 1.11, 1.73 0.004 
Obese 19,676 2,237 3.15 2.55, 3.88 <0.000 





Table 2.5. Incidental Risk of Type II Diabetes Mellitus Associated with the Interaction of 
Study Group and Age Greater or Less than 45 years of Age among Study Patients 
independent variables 







ratio 95% CI p 
      
Demographics 
Exposure group           
At-risk for diabetes and <45 years 7,828 238 ---- ---- ---- 
At-risk for diabetes and ≥45 years 11,460 1,013 1.86 1.54, 2.25 <0.000 
Unconfirmed prediabetes and <45 years 2,810 185 2.32 1.81, 2.99 <0.000 
Unconfirmed prediabetes and ≥45 years 10,195 1,308 2.90 2.35, 3.57 <0.000 
Confirmed prediabetes and <45 years 356 38 3.70 2.37, 5.77 <0.000 
Confirmed prediabetes and ≥45 years 1,189 290 5.23 4.16, 6.58 <0.000 
Female sex 15,523 1,392 1.00 0.86, 1.16 0.978 
Race           
White 28,474 2,598 ---- ---- ---- 
Asian 786 64 1.69 0.92, 3.11 0.093 
Black 525 32 1.13 0.74, 1.73 0.560 
Hispanic 841 8 0.78 0.25, 2.42 0.670 
Other 1,102 79 1.46 1.07, 1.97 0.016 
Unknown 2,110 102 1.24 0.98, 1.57 0.074 
Clinical Characteristics 
Chronic conditions           
Depression 6,190 646 0.87 0.76, 0.99 0.042 
Coronary Heart Disease 3,183 374 1.22 1.06, 1.42 0.007 
Congestive Heart Failure 1,173 142 0.95 0.76, 0.99 0.042 
Atrial Fibrillation 899 82 0.71 0.54, 0.93 0.014 
High Blood Pressure 10,456 1,311 1.14 1.01, 1.29 0.043 
Medication class           
Anti-hypertension 8,617 993 0.88 0.75, 1.03 0.114 
Atypical-neuroleptics 854 85 0.32 0.10, 1.05 0.060 
Metformin 535 190 3.78 3.09, 4.64 <0.000 
Statin 6,556 746 1.09 0.94, 1.25 0.247 
BMI class at baseline           
Normal 2,573 106 ---- ---- ---- 
Underweight 175 13 2.47 1.24, 4.92 0.010 
Overweight 11,414 527 1.30 1.02, 1.65 0.032 
Obese 19,676 2,237 2.32 1.81, 2.97 <0.000 









2004, annualized incidence rates of progression to diabetes in patients with various 
categories of glucose intolerance were comparable (15–25%) to results seen in this 
study.20 In subsequent major studies, annual progression estimates were also similar: 
11% in the Diabetes Prevention Program (DPP) outcomes study21,22 and 9% in 
participants with impaired fasting glucose and 7% in those with HbA1c between 5.7–
6.4% enrolled in a Japanese population-based study.23  
The incidence rates detected within this study are clinically concerning and will 
be financially devastating to not only our transforming delivery system, but also to the 
patient and their families as we move into an accountable environment for care delivery. 
In the study, the majority of participants had not even reached a Medicare eligible age, 
demonstrating that those who develop chronic diseases will have to live with their 
disease for many years to come. In a series of rigorous cost analyses conducted over the 
past decade, the American Diabetes Association estimated that Americans with 
diagnosed diabetes have annual medical expenditures that are $7,900 more, or 
approximately 2.3 times higher, than they would be in the absence of diabetes ($13,700 
vs. $5,800).4 Therefore, it is important to identify not only the triggers that predispose 
progression but also potential interventions that could impede or slow incident disease 
over time. 
Earlier identification of patients with preventable disease is one mechanism for 
redesigning healthcare within a transforming delivery system. While a large body of 
literature supports the effectiveness of intervening on a population of patients with a 
confirmed diagnosis of preDM or those with identifiable risk factors for disease, much 




greater risk of T2DM can order laboratory tests such as FPG or HbA1c to confirm their 
suspicions. However, a significant number of patients (n= 13,005 in our study) are not 
yet on their radar, but were found to have elevated FPG from chemistry panels ordered 
while evaluating or screening for other conditions. This confirms our findings that 
patients with a confirmed or unconfirmed diagnosis of preDM demonstrated an 
incremental risk of developing T2DM in comparison to patients with only risk factors for 
disease. Identifying patients at greatest risk or those with the largest benefit will be one 
mechanism to manage the population’s health in the future to delay or avoid diagnosis of 
T2DM. 
The findings of this study clearly support previous work that demonstrate the 
increased risk of incident T2DM disease among exposed groups, yet also contributes to a 
limited body of knowledge surrounding methods to identify unconfirmed preDM and 
track outcomes over time. It should be noted that while confirmation of preDM increases 
the risk of T2DM, we also confirmed that increasing age also independently increases a 
person’s chance of diagnosis. This finding lends evidence to the ADA criteria that 
recommends screening for T2DM and preDM in otherwise healthy individual’s ≥45 
years of age at least every 3 years.4,7 Patients with depression at study entry seemed to 
have a protective effect for developing T2DM, which may be a mechanism of high 
functioning, multidisciplinary primary care teams to guide patients to care faster. This 
finding warrants further study. 
Limitations 
The study groups were carefully selected according to criteria found within the 




selection bias that still remain, affecting the results observed. Patients within the 
confirmed and unconfirmed preDM groups only had one documented laboratory test, 
although most clinical experts will require at least two tests to confirm suspicions of 
preDM. Patients within the at-risk study group may have variation in the ability to 
identify risk factors. When possible, validated IH registries were used to identify risk 
among patients (i.e., hypertension, polycystic ovary syndrome, gestational diabetes, and 
birth weights >9lbs); however, the ability to identify patients with family history of 
diabetes may be more difficult to classify because it relies on patient self-report and 
providers to document this in the medical record. Patients with prevalent T2DM 
diagnosis were excluded, yet there remains a possibility that their diagnosis was not 
identified due to the definition criteria or care that occurred outside of the IH system. 
The percentage of patients who were loss to follow-up was not defined or captured in 
this study. Patient encounters that occurred outside of the IH delivery system would not 
be captured within this analysis; however, IH does encompass roughly 60% of the care 
delivered within Utah. Since the IH Diabetes Registry does not distinguish between Type 
1 or Type 2 diabetes mellitus, our primary outcome may still include both types of the 
disease. To account for these limitations, pediatric patients were excluded from the study 
population and the provider population was also limited to only primary care providers 
and did not consider those who delivered specialty care, such as endocrinologists and 
diabetologists. Female patients who consider their obstetrician or gynecologist as the 
provider who delivers their care primarily were not studied in this analysis and may 
warrant further study to determine their risk of T2DM. While the methodology used in 




patients received care, it might not account for all variation in practice which could affect 
the observed results. It should also be acknowledged that the study population was 
largely Caucasian and may not be generalizable to populations outside of IH. Patients 
from outside of the state of Utah do access the delivery system, yet are among the 
minority of IH encounters. Social determinants of health such as where the patient was 
born, their current living conditions, and education and income level have also been 
associated with health outcomes, but were not available for study.  
Conclusions 
Patients with unconfirmed and confirmed preDM had a higher risk of T2DM as 
compared to patients with only risk factors for disease. While early identification and 
risk stratification of T2DM is indispensable, the real opportunity lies with creating 
intensive lifestyle interventions that are attainable and affordable for patients, can sustain 
positive results over time, and can be scaled to meet the growing needs of our 
populations. While difficult to motivate these practices (e.g., proper nutrition, weight 
loss, physical activity), empowering patients with their risk status may activate them as 
partners in health. Coupling these interventions with integrative care management 
strategies, team-based care delivery, and payment reform geared towards value and 
service will only emphasize proactive identification and assessment for those at-risk for 
chronic disease progression and improve the overall health for most targeted populations, 
not just for patients at-risk for T2DM. 
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STEPPING BACK TO MOVE FORWARD: EVALUATING 
 
THE EFFECTIVENESS OF A DIABETES PREVENTION 
 
PROGRAM WITHIN A LARGE INTEGRATED 
 
HEALTHCARE DELIVERY SYSTEM2 
Abstract 
Objective 
To evaluate the short-term effectiveness of the Intermountain Healthcare (IH) 
Diabetes Prevention Program (DPP) for patients with prediabetes (preDM) deployed 
within primary care clinics. 
Study Design 
A prospective, quasi-experimental study design was used to deploy the DPP 
within the IH system to identify patients with preDM, create a provider referral process 
to enroll patients within the DPP, standardize the counseling received, and to determine 
the short-term impact of a DPP-based intervention on patients with preDM targeting a 
primary goal of a 5% weight loss within 6 months of enrollment. 
Study Population 
An adult population aged ≥18-75 years who met the American Diabetes 
                                                 





Association criteria for preDM (HbA1c 5.7- 6.49% or Fasting Plasma Glucose 100-
125mg/dL) were attributed to an IH primary care provider. Primary care providers were 
provided a list of their patients who met these laboratory criteria, and were encouraged to 
invite patients to participate in the DPP. Patients were excluded for study if they had 
been diagnosed with type II diabetes mellitus (T2DM) prior to or within 2 months of 
study enrollment, had a known death within the study period, or ever had weight loss 
surgery. Patients who attended DPP counseling between August 2013 and July 2014 
were considered as the intervention (or DPP) group. The DPP group was matched using 
propensity scores at a 1:4 ratio with a control group of preDM patients who did not 
participate in DPP (no-DPP group). 
Results 
Of the 17,142 IH patients who were identified as meeting criteria for preDM, 
6,842 had an in-person office with their provider. Patients receiving DPP education 
(n=573) were matched using patient demographics and clinical characteristics to the no-
DPP group (n=2292). Average age was 58.4 years and 62% were female. Based on 
multivariate logistic regression, the DPP group was more likely to achieve a 5% weight 
loss within 6 months (OR 1.72; 95% CI 1.29, 2.34; p<0.001) and less likely to have 
incident T2DM (OR 0.45; 95% CI 0.24, 0.84; p=0.012) when compared to the no-DPP 
group.  
Conclusions 
DPP-based lifestyle interventions demonstrated significant reduction in body 





According to the American Diabetes Association (ADA), approximately 29.1 
million Americans are diagnosed with Type II Diabetes Mellitus (T2DM) and there are 
over 1.7 million new cases diagnosed each year.1-3 Even more overwhelming are the 
estimates that 37% of US adults have prediabetes (preDM) with a prevalence rate of 
greater than 75% in those aged 65 years and older.1-3 However, roughly 86% of those 
with preDM are not aware of their condition.1-5 Diabetes can lead to heart disease and 
stroke, blindness, kidney disease, amputation, and eventually death when not properly 
managed.6 In 2010, it was the seventh leading cause of death in the United States.6 
The ability to identify and intervene on populations at risk for T2DM represents 
an opportunity to reduce both the incidence and cost of disease over time. Extensive 
literature has demonstrated that intensive lifestyle interventions which focus on healthful 
nutrition, physical activity, weight management, and coping mechanisms are effective at 
decreasing the incidence of T2DM by as much as 58%.7-11 Additional studies have 
shown that intensive lifestyle interventions outperform other medical management 
methods such as metformin.5,7-12 Among patients who were recruited and enrolled from a 
primary care setting for DPP-based lifestyle interventions, 37% among coach-led groups 
and 35.9% among self-directed (as compared to 14.4% in the usual care group) were able 
to achieve a 7% weight loss goal.11 Within a DPP-based intervention delivered by trained 
diabetic educators, over 40% of their population was able to achieve a 5% weight loss.13 
While these studies provide an informative perspective on the efficacy of lifestyle 
interventions, clinical effectiveness alone is not enough to demonstrate a broader public 
health impact.14 Additional evidence supporting the external validity of interventions 




decisions for clinical practice.15 
Intermountain Healthcare (IH) began work in early 2013 to identify the 
population at-risk for diabetes; institute an expert clinical development team to create a 
care process for the identification and management of patients with preDM; analyze 
current organizational health promotion and disease prevention infrastructure; and to 
create an education and referral process for patients identified with preDM. Based on a 
modified form of the National Diabetes Prevention Program (NDPP),10 IH piloted its 
Diabetes Prevention Program (DPP) in 5 primary care clinics and later deployed it 
system-wide as of January 2014. The IH DPP uniquely includes three different paths for 
participation: a two-hour introduction group class, individualized nutritional counseling, 
and an intensive lifestyle intervention.  
It is unknown whether the IH DPP, implemented within a large integrated 
healthcare delivery system while utilizing multiple pathways for counseling, can support 
preDM patients in attaining a 5% weight loss within 6 months of enrollment. The 
purpose of this study is to evaluate the short-term impact of the DPP and determine the 
associated clinical outcomes and healthcare utilization patterns among enrolled patients 
as compared to patients with preDM who did not participate.  
Methods 
A prospective, quasi-experimental design was utilized to deploy the DPP within 
IH’s delivery system. The primary outcome was to determine the association of a 5% 
weight loss at 6 months among patients who enroll in the DPP. Secondary outcomes of 
interest included incident diagnosis of T2DM, change in weight over the intervention 





Intermountain Healthcare (IH) is an integrated delivery system of 22 hospitals, a 
Medical Group with more than 185 ambulatory physician clinics and approximately 
1,100 primary and secondary care physicians, and an affiliated health plan, that provides 
more than half of all healthcare services within Utah and southeastern Idaho.16,17 IH’s 
new mission, ‘to help people live the healthiest lives possible’, is actualized through a 
clinical integration structure (Clinical Programs) that is driven to optimize clinical work 
processes through a culture of accountable leadership, continuous quality improvement, 
and measurement of patient outcomes and delivery system costs.16  
Diabetes Prevention Program 
In early 2013, the Primary Care Clinical Program began work on the creation of a 
defined DPP to deploy within primary care clinics at IH. Previously, there was no 
systematic way to identify patients who met the criteria of preDM and there was no 
standardized way for providers to refer patients to existing wellness programs. This 
program identified patients who meet criteria for preDM (HbA1c 5.7-6.49% or Fasting 
Plasma Glucose 100-125mg/dL) and provided an introductory class focused on 
awareness and goal setting for patients, while leveraging existing wellness initiatives for 
intensive lifestyle and behavior change education demonstrated as effective in the peer-
reviewed literature. Patients were then allowed to enroll in any or all of the three 
differing pathways that make up the DPP (Figure 3.1).  
Prediabetes 101 
An introductory, two-hour group class for preDM patients (Prediabetes 101) 





Figure 3.1.  Intermountain Healthcare Diabetes Prevention Program (DPP) Flow 
Process. ©2014, Intermountain Healthcare. Used with permission. All 




being active and understanding the benefits of physical activity; problem solving to 
prevent short-term complications; healthy coping exercises to understand how preDM 
may affect emotional health; and reducing risks of long-term complications. Utilizing a 
group approach to instruction, this class was taught by dietitians who are certified 
diabetic educators and included components of goal setting and engagement/behavioral 
evaluation. Class participation was free of charge to patients within the IH system. 
Medical Nutrition Therapy 
Medical Nutrition Therapy (MNT), or nutrition counseling, includes individual 
sessions provided by Registered Dieticians. These sessions were highly individualized, 
catering materials and education to the needs of each patient. Patients were provided 
with a personalized eating plan and personalized support. In addition, dietitians were 
encouraged to provide patients with preDM structured educational content aimed at 
diabetes prevention. Three to five two-hour sessions per year are currently fully covered 
by several commercial health insurance plans as directed by the Affordable Care Act.18-20  
Weigh to Health 
The Weigh to Health (W2H) nutrition program is an IH hospital-based behavioral 
program offered over 12 class periods within a 6-month period for individuals who are 
overweight and obese. The program was: (a) constructed from current research and 
effective behavioral methods shown to promote and sustain weight loss and improve 
physical activity; (b) standardized across all IH hospitals; and (c) provided by Registered 
Dietitians with training and experience in weight management. For individuals that 
achieve attendance goals and lifestyle changes, some commercial health plans will fully 




through group and individual sessions and this curriculum most closely resembles 
education supported by the NDPP10 (≥70% overlap), and caters to a majority of 
individuals that meet the preDM criteria.  
Study Participants 
A source population of adult patients (aged 18-75 years) who met criteria for 
preDM within the last 3 years was obtained through a query of IH’s Enterprise Data 
Warehouse (EDW). Patients were attributed to a primary care provider who provided the 
plurality of qualifying services (Current Procedural Terminology codes for outpatient 
visit, preventive medicine visit, or wellness visit: 9920x, 9921x, 99385-87, 99395-97, 
G0101, G0402, G0438) in a given calendar year with most recent service date breaking 
any ties. Patient-level data were distributed to the providers and practice support staff so 
patients could be identified with preDM prior to arriving for their appointments. 
Providers were encouraged to invite eligible patients to participate in the DPP during 
their next in-person office visit. Patients were excluded for study if they had been 
diagnosed with diabetes prior or within 2 months of enrollment, had a known death 
within the study period, or ever had weight loss surgery. Patients who attended a 
Prediabetes 101 class, MNT, or W2H between August 2013 and July 2014 were 
considered as the intervention (DPP) group. Patients with preDM who were attributed to 
the same group of PCPs, and had the opportunity to enroll in the DPP, but did not, were 
considered as the control (no-DPP) group. This study was approved by the IH 






As determined by clinical health characteristics, patients within the study groups 
were compared to assess whether differences in patient demographics and clinical 
characteristics existed prior to study enrollment. Baseline demographics included age, 
sex, race/ethnicity, and insurance status. Clinical characteristics for the study cohort 
included the proportion of patients with chronic conditions prior to study enrollment 
including: depression, coronary heart disease, congestive heart failure, atrial fibrillation, 
and high blood pressure. Criteria for chronic conditions are different for each condition; 
however, they are based on diagnosis codes and encounter data, and approved by an 
internal expert committee of practicing providers (see Table 2.2). The duration of preDM 
diagnosis was estimated based on the first documentation of laboratory values within the 
EDW system and was categorized into: less than 5 years duration, 5-9 years duration, 
and greater than 10 years of duration. The most recent (≤12 months prior to enrollment) 
clinical biometric measures were collected including: height, weight, body mass index 
class (underweight, normal, overweight, or obese), HbA1c, fasting plasma glucose, total 
cholesterol, High-Density Lipoprotein, and Low-Density Lipoprotein. Also included 
were the medications that were ordered prior to study enrollment and categorized as 
pertinent medication classes for study (anti-hypertensive, atypical-neuroleptics, 
metformin, and statins).  
Study Outcomes 
Achieving a 5% weight loss within a window of 5-12 months after study 




because evidence-based guidelines suggest semi-annual medical follow up for patients 
identified with preDM, and is paralleled to the outcome intervals within the literature.7-
11,21 Secondary outcomes included: incident diagnosis of T2DM, change in weight, and 
healthcare utilization (encounters with primary care physicians, specialty care 
physicians, lifestyle and weight management counseling, ED visits, and hospital 
admissions) among study groups assessed within a window of 5-12 months after 
enrollment. 
Statistical Analyses 
Roughly 17,142 patients were identified that met the preDM criteria within the 
IH system during the study period. Of these, 6,842 patients met the study criteria for 
enrollment. Expecting a 10% invitation rate among the eligible population 
(invited/eligible) and a 90% participation rate among those invited to participate 
(enrolled/invited), it was estimated that roughly 511 patients would participate. Those 
who did not participate were used as our control population. Because the control 
population available was much larger than the intervention population, patients were 
matched in a 1:4 ratio based on propensity score matching to their nearest neighbor to 
identify control patients that most likely resembled that of a DPP patient. Characteristics 
used for matching were: age; sex; race/ethnicity; duration of preDM; baseline weight; 
and prevalence of depression, high blood pressure, coronary artery disease, congestive 
heart failure, and atrial fibrillation. This weighting method produced an “average 
treatment effect on the treated” (ATT) estimates, answering the question: “Among 
control patients closely resembling the DPP patients, what outcomes were associated 




estimated that enrollment of approximately 254 experimental subjects and 1016 control 
patients would provide > 80% power with alpha = 0.05 to detect a 5% weight loss.  
To describe the similarities and differences among the study groups at baseline, a 
chi-square analysis was computed for categorical variables. Continuous variables were 
compared between study groups using a student’s t test. 
Conditional logistic regression modeling derived to test the null hypothesis that 
the association of achieving a 5% weight loss was no different among participants and 
nonparticipants. Patients categorized as no-DPP were considered the referent group. 
Odds ratios were generated after adjustment for baseline differences including 
demographic and clinical characteristics that are well known to affect the ability to 
achieve the 5% weight loss. Similarly, this method was used to determine the incidence 
of T2DM among groups. 
For measurement of change in weight over the study period, difference-in-
difference regression was used to identify the association and magnitude of weight loss 
among study groups from baseline to follow-up. Incidence rates (#events/patient-years) 
were utilized to test the association of DPP participation and specific healthcare 
utilization within the study period. An incidence rate ratio with corresponding 95% 
confidence intervals was computed to determine the probability of an event occurring 
among study groups. 
For all analyses, a p-value ≤0.05 was considered statistically significant. All data 





As documented in Figure 3.2, 17,142 patients were identified with the IH 
delivery system as meeting criteria for preDM within the last 3 years of the study period. 
Of these, 7,481 had an in-person office visit with their provider during the study period 
and had the opportunity to be invited to the DPP program. 639 patients were excluded 
from analysis (340 had T2DM prior or within 2 months of enrollment; 77 were invited 
but did not participate; 102 had miscoded data related to preDM diagnosis; 63 had 
medical condition not related to weight loss or diabetes prevention; 38 began education 
prior to DPP program initiation; 9 underwent weight loss surgery; 8 were <18 years old; 
and 2 died). Of those remaining (n=6,842), 573 subjects (8.4%) received DPP education. 
These case-patients were compared with no-DPP patients (n=2292) who served as the 
control group. Of the DPP group, 384 (67%) participated in the Prediabetes 101 class, 
213 (37%) in MNT, and 54 (9%) in W2H (patients could participate in any of all of the 
different DPP pathways, and thus the proportion among the group does not add up to 
100%). Only 63 patients participated in more than one DPP pathway, with all of them 
participating in the Prediabetes 101 and MNT classes combined. 
Baseline demographic and clinical characteristics are summarized in Table 3.1. 
Due to the use of propensity score matching to select the control group, there were no 
statistical differences among patient characteristics used within the weighting (age; sex; 
race/ethnicity; duration of preDM; baseline weight; and prevalence of depression, high 
blood pressure, coronary artery disease, congestive heart failure, and atrial fibrillation). 
Of the other baseline characteristics considered, DPP patients were more likely to be 
uninsured/self-pay (11.1% vs. 6.0%; p=0.01), prescribed metformin (21.6% vs. 15.3%; 
















Table 3.1. Baseline Characteristics of the Study Population Stratified  
by Diabetes Prevention Program Participation 
Variables 
DPP Participants                                               
n =  573 
Control Group                         
n = 2292 
p n M ± SD or % n M ± SD or % 
      
Demographics 
Age at Study Enrollment, yrs 573 58.53±13.32 2292 58.38± 11.04 0.821 
Gender, %          0.537 
Male 212 37.12 886 38.66  
Female 356 62.88 1,406 61.34   
Race/ethnicity     0.786 
White 506 88.43 1,984 86.56  
Hispanic 44 7.64 192 8.38   
Black 4 0.66 18 0.79   
Asian 10 1.75 44 1.92   
Other/Unknown 9 1.53 54 2.36   
Insurance          0.01 
Commercial 294 51.31 1,252 54.62  
Medicare 194 33.84 816 35.60   
Medicaid 21 3.71 86 3.75   
Self-Pay/Uninsured 64 11.14 138 6.02   
Clinical Characteristics  
Prediabetes duration     0.606 
<5 year 458 79.91 1,856 80.98  
5-9 years 100 17.47 392 17.10   
>10 years 15 2.62 44 1.92   
Chronic Conditions, %           
Depression 272 47.38 1,060 46.25 0.657 
Coronary Heart Disease 114 19.87 444 19.37 0.806 
Congestive Heart Failure 51 8.95 216 9.42 0.751 
Atrial Fibrillation 45 7.86 156 6.81 0.419 
High Blood Pressure 336 58.73 1,348 58.81 0.975 
Medication class, %      
Anti-hypertensive 274 47.82 1,160 50.61 0.275 
Anti-neurolyptics 55 9.61 204 8.90 0.630 
Metformin 124 21.62 350 15.27 0.011 
Statin 304 53.06 1,201 52.40 0.797 
Weight, kg 573 98.81±25.37 2292 98.73±26.54 0.952 
HbA1c, % 381 5.89±0.28 1431 5.96±0.52 0.015 
LDL, mg/dL 392 106.41±35.02 1531 107.04±34.67 0.763 
HDL, mg/dL 408 46.70±13.84 1568 46.41±13.54 0.723 
Cholesterol, mg/dL 406 184.31±40.70 1569 185.63±39.67 0.578 
Physical Activity, min/week 275 138.78±149.49 557 158.04±244.24 0.177 
BMI Class, %     0.388 
Underweight 2 0.44 13 0.58  
Normal 38 7.10 207 9.31   
Overweight 130 24.83 502 22.58   
Obese 355 67.63 1,501 67.52   





not enrolled. Physical activity (min/week) and other pertinent laboratory values (LDL, 
HDL, and cholesterol) did not significantly differ between groups at baseline. 
After adjustment for all confounders listed in Table 3.2, patients in the DPP 
group were 70% more likely to achieve a 5% weight loss as compared to the control 
group (OR 1.70; 95%CI 1.29, 2.25; p<0.001). DPP patients were also less likely to have 
an incident diagnosis of T2DM during the study period (OR 0.49; 95%CI 0.28, 0.86; 
p=0.012). There was no statistical difference in the achievement of 5% weight loss when 
comparing the different DPP pathways (W2H vs Prediabetes 101: OR=0.65; 
95%CI=0.24, 1.76; p=0.40; MNT vs Prediabetes 101: OR=1.39; 95%CI=0.76, 2.53; 
p=0.28; MNT/101 vs Prediabetes 101: OR=0.99; 95%CI=0.43, 2.28; p=0.99). 
As documented in Table 3.3, there were greater rates (#events/patient year) of 
PCP visits (4.0 vs 3.6; p=0.006), visits to a specialty providers (4.8 vs1.3; p<0.0001), and 
lifestyle and weight management counseling attempts (3.1 vs 1.0; p<0.0001) that 
occurred in the DPP group as compared with the no-DPP group. There were no 
significant differences in acute care encounters among study groups. 
DPP participants were more likely to have any weight loss (44.1% vs. 35.3%; 
p<0.0001) and the largest change in weight (-1.8kg vs -0.3 kg; p=0.009) when compared 
to no-DPP participants (Figure 3.2). After comparing the change in weight over time 
using difference in difference regression modeling, DPP participation showed a trend 
toward significance with a greater reduction in weight when compared to the no-DPP 






Table 3.2. Conditional Logistic Regression Modeling for Achievement of a 5% Weight 
Loss and Incidence of Type II Diabetes Mellitus Stratified by 
Diabetes Prevention Program Participation 
Independent 
variables #pts 











          
Study Group 
Control group 2292 328 ---- ---- ---- 115 ---- ---- ---- 
DPP participant 
group 
573 128 1.70 1.29, 
2.25 




Age, yrs 2865 456 1.00 0.99, 
1.02 
0.365 127 1.01 1.00, 
1.03 
0.174 
Female sex 1762 294 1.03 0.84, 
1.25 
0.790 132 0.58 0.45, 
0.76 
0.000 
Race          
White 2490 409 ---- ---- ---- 111 ---- ---- ---- 
Asian 54 7 0.70 0.48, 
1.02 
0.066 10 0.99 0.61, 
1.60 
0.966 
Black 22 3 0.43 0.10, 
1.86 
0.261 2 0.96 0.23, 
4.08 
0.954 
Hispanic 236 21 1.06 0.53, 
2.11 
0.877 3 1.55 0.69, 
3.47 
0.289 
Other/Unknown 63 16 1.46 0.81, 
2.62 
0.209 1 0.62 0.22, 
1.74 
0.368 
Insurance          









































         
         <5 year 2314 358 ---- ---- ---- 108 ---- ---- ---- 
         5-9 years 492 82 0.95 0.76, 
0.66 
0.687 16 0.60 0.42, 
0.84 
0.003 
         >10 years 59 16 1.15 1.20, 
2.01 





         
Depression 1332 221 0.94 0.77, 
1.15 





558 79 0.80 0.62, 
1.04 
0.097 23 1.00 0.71, 
1.41 
0.990 
Heart failure 267 53 1.25 0.90, 
1.75 
0.188 11 1.08 0.67, 
1.76 
0.855 





Table 3.2. Continued 
Independent 
variables #pts 











          
Atrial 
fibrillation 
201 25 1.00 0.69, 
1.43 





1684 261 0.93 0.73, 
1.18 
0.544 79 0.93 0.67, 
1.29 
0.681 
Medication class          
Anti-
hypertension 
1434 223 0.95 0.75, 
1.20 





259 62 1.52 1.14, 
2.01 
0.004 5 0.91 0.55, 
1.52 
0.715 
Metformin 474 87 0.97 0.76, 
1.24 
0.799 51 5.83 4.52, 
7.53 
0.000 
Statin 1505 236 0.94 0.77, 
1.14 





2865 456 1.01 1.00, 
1.01 
0.003 127 1.00 1.00, 
1.01 
0.345 
          
Note. OR: Odds Ratio; CI: Confidence Interval; pts: patients; T2DM: Type II Diabetes 
Mellitus; DPP: Diabetes Prevention Program 
 




Table 3.3. The Incidence Rate of Healthcare Utilization Encounters Stratified by 
Diabetes Prevention Program Participation 
 
DPP participants                                               
n = 573 
Control group                                
n = 2292 
Rate 








        
# of visits to a PCP 1342 3.97 7210 3.66 1.09 1.02, 
1.15 
0.006 
        
# of visits to a 
Specialista 
1626 4.82 7282 3.70 1.30 1.23, 
1.38 
<0.0001 
        




1037 3.07 2063 1.05 2.93 2.72, 
3.16 
<0.0001 
        
# of ED Visits 92 0.27 591 0.30 0.91 0.72, 
1.13 
0.39 
        
# of hospital 
admissions 
52 0.15 242 0.12 1.25 0.91, 
1.70 
0.14 
        
Note. PCP: primary care physician; DPP: Diabetes Prevention Program; CI: confidence 
interval; ED: emergency department 
 
a Number of visits to provider without primary care specialty designation 
 
b Number of counseling encounters for either nutrition, physical activity, or the Diabetes 






Figure 3.3.  Secondary Outcomes of (a) Change in Weight (Kilograms) and (b) the Proportion of Patients Who Achieved Any 






This primary-care-based pragmatic evaluation demonstrated that DPP-based 
lifestyle interventions led to significant reductions in body weight (measured by 
achievement of a 5% reduction in body weight and overall change in weight) and were 
accompanied by a significant reduction in T2DM incidence when compared to a patient 
group who did not enroll. DPP participants experienced an increased rate of follow up 
with primary and specialty care providers and increased lifestyle and weight 
management counseling as compared to patients with preDM who did not participate 
over a 6-month period. However, routine clinical follow-up according to evidence-based 
guidelines for this patient population could still improve (only 29% of study population 
had routine clinical biometrics such as physical activity per week and common 
laboratories documented within 5-12 months after participation). Also, when the 
different DPP pathways were compared, there seemed to be no statistical differences in 
outcomes, suggesting that patients may inherently gravitate towards counseling that best 
fits their individual needs. 
While a large body of literature supports the internal validity of lifestyle and 
weight management counseling in improving outcomes related to weight loss and 
diabetes prevention,7-11  much less evidence exist on outcomes associated with 
deployment of diabetes prevention efforts within a large integrated delivery system. The 
findings of this study support previous literature that demonstrate among patients who 
were recruited and enrolled from a primary care setting for DPP-based lifestyle 
interventions, 35-40% were able to achieve a clinically significant weight loss. 11,13 




DPP led by the Centers for Disease Control and Prevention and the YMCA, 72% 
completed the 12-month program (compared to 68% in this study) and the average 
weight loss was 4.8%.22 These studies lend credence to the effectiveness of deploying 
these strategies within pragmatic clinical or community-based settings while validating 
the results from this study.  
However, even with this success, lifestyle change programs such as the IH DPP 
remain unavailable to most Americans with preDM, most notably those with Medicare 
and Medicaid insurance, who do not provide reimbursement for diabetes prevention 
programs, nor do they cover the cost of laboratory testing for diagnosis of preDM.23 As 
evidenced by the large number of preDM patients identified with the IH system, the 
majority are at-risk for developing T2DM and could receive benefit from participating in 
nutritional and physical activity counseling. In a systematic review of over 3303 
publications, Walden et al. present findings that suggest a range of trained 
interventionists, following structured protocols, from a variety of educational 
backgrounds could be considered for delivering weight loss therapy, rather than relying 
on the primary care practitioners to deliver such care.23 In this study, we identified 
>17,000 patients who met the laboratory criteria of preDM, yet only a small proportion 
of this group was enrolled due to resource and clinical constraints within primary care 
teams.  
DPP enrollment seemed to be one of only a few indicators of successful 
achievement of weight loss and the reduction in T2DM diagnosis after enrollment, even 
after adjustment for differences in patient characteristics among groups. Furthermore, 




with PCPs, specialists, and those that were delivering lifestyle and weight management 
counseling. While these outcomes may reveal a patient population who is more engaged 
and accountable for their care, nevertheless, this may also be an indication that DPP 
participants are more likely to follow the established care process for preDM, 
contributing to their positive weight loss results. Both outcomes will warrant further 
longitudinal study to understand how efficiently the program can reach other patients 
groups and increase the ability to predict which patients are more likely to participate 
and achieve the desired weight loss goals.  
Limitations 
The study groups were carefully selected according to criteria found within the 
literature, but there may be inherent unaccounted differences due to data miscoding or 
selection bias that still remain affecting the results observed. Patients who enrolled with 
the DPP group may have been more “ready to change” than those that did not participate. 
However, the control group was carefully selected to only include those who had the 
opportunity to be invited by their PCP (but were not) and excluded patients who were 
invited but decided not to enroll. Female patients who consider their obstetrician or 
gynecologist as the provider who delivers their care primarily were not studied in this 
analysis and may warrant further study. Additional analyses will be needed to determine 
the patient characteristics of those who are more likely to participate and were outside of 
the scope of this current study.  
Due to the different counseling pathways within the IH DPP, there may be 
unaccounted differences by evaluating them collectively. However, when these pathways 




loss. Further longitudinal study will be needed to confirm this finding.  
As demonstrated by some statistical differences among study groups in their 
baseline characteristics, DPP patients tended to be more likely to be prescribed 
metformin and have a lower HbA1c; however, these differences were accounted for in 
the regression models.  
Since the IH Diabetes Registry does not distinguish between Type 1 or Type 2 
diabetes mellitus, the primary outcome may still include both types of the disease. To 
account for this possibility, patients less than 18 years of age and those attributed to 
endocrinologists or diabetologists were not included for study. It should also be 
acknowledged that the study population was largely derived from patients who had 
visited a primary care provider within a large integrated healthcare system and may not 
be generalizable to populations outside of IH.  
Data elements that include social determinants of health (income and education 
level, number of family members or dependents, and the contextual elements of the 
neighborhood or geographical location where the patient lives) have been shown to be 
predictive of positive outcomes in weight loss; however, these were not available for 
study. Other clinical biometrics (i.e., physical activity per week and common 
laboratories) were queried within the IH EDW, but very few patients (29%) in any of the 
study groups had these services performed at study completion. Quality improvements 
efforts are currently underway to ensure adherence to the care process for preDM and 






Within a pragmatic clinical setting, successful adaptation of DPP-based lifestyle 
interventions among preDM patients was associated with achievement of weight loss 
goals and a reduction in overall incidence of T2DM during the study period. Additional 
study is needed to determine the reach or representativeness of DPP participants; 
adoption or the number of providers and clinical settings who were willing to initiate the 
intervention; and the implementation, or fidelity to various elements of the IH DPP 
intervention. As demonstrated by the large population that was identified within this 
study, leveraging technology may be a key strategy to reach more affected populations 
and scale these established interventions for the masses. Finally, just as overall health 
does not arise from only a single factor, scalable interventions geared towards patient 
activation and accountability through structured behavior change practices will only 
emerge from concerted and collaborative efforts that stretch across the care continuum. 
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EVALUATION OF A DIABETES PREVENTION PROGRAM 
 
UTILIZING THE RE-AIM FRAMEWORK3 
Abstract 
Objective 
Pragmatic evaluation of new interventions implemented in healthcare is one of 
the key issues addressing the gap between research and practice, but is seldom assessed 
in implementation studies. The aim of this study was to evaluate the reach, effectiveness, 
adoption, and implementation of a Diabetes Prevention Program (DPP) within a large, 
integrative delivery system among patients identified with prediabetes (preDM).  
Methods 
Using the Intermountain Healthcare (IH) Enterprise Data Warehouse (EDW), 
adult primary care patients (aged ≥18-75 years) who met the American Diabetes 
Association criteria for preDM (HbA1c 5.7- 6.49% or Fasting Plasma Glucose 100-
125mg/dL) were attributed to a primary care provider (PCP) during 2013-2014. PCPs 
were provided a list of their patients who met these laboratory criteria and encouraged to 
invite patients during their next in-person office visit to participate in the DPP. Using the 
RE-AIM framework at 12 months post deployment, we evaluated: reach with data on 
                                                 





patient identification, participation, and representativeness; effectiveness with data on the 
odds of attaining a 5% weight loss; adoption with monitoring of organizational diffusion 
among providers/clinics; and implementation with the fidelity of the education as it was 
deployed throughout the delivery system. 
Results 
Roughly 8% of eligible patients were enrolled. Likelihood of participation was 
higher among patients who were: female, aged >70 years, overweight, had depression 
and higher baseline weight, and those prescribed metformin. Likelihood of participation 
was lower in patients with 5-9 years duration of preDM diagnosis. DPP participants were 
more likely to achieve a 5% weight loss within 6 months (OR 1.72; 95% CI 1.29, 2.34; 
p<0.001) when compared to a control group that did not participate. Providers from 7 of 
8 regions referred patients to the DPP, with 174 providers at 53 clinics enrolling patients 
within the first 12 months of the program. There were on average 2.3 (range 1-16) DPP 
counseling encounters during follow-up. 
Conclusions 
DPP-based lifestyle interventions deployed within IH’s delivery system 
demonstrated encouraging potential for patients identified with preDM and for the 
organization which provides their care. This study may inform pragmatic implementation 
of future evidence-based interventions for other health networks, physicians, and payers.  
Introduction 
It is estimated that 86 million adults, more than one-third of Americans aged 20 




Mellitus (T2DM).1 However, only one in 14 (7.1%) of adults in the US have been told by 
a healthcare provider that they have the condition.1  
Diabetes results from a combination of genetic predisposition, as well as 
behavioral and environmental risk factors. However, there is strong evidence that such 
modifiable risk factors like bad health behaviors, nutrition, obesity, and physical 
inactivity are the main environmental determinants of the disease.2 General consensus 
among practitioners is that to combat type II diabetes mellitus (T2DM), we must first 
undergo measures to prevent it.  
Several randomized clinical trials have solidified the efficacy of intensive 
lifestyle interventions to support weight loss and weight loss maintenance as the key to 
preventing progression of diabetes for those at-risk for disease.3-8 The Diabetes 
Prevention Program Outcomes Study (DPPOS) demonstrated that prevention or delay of 
diabetes with lifestyle intervention or metformin can persist for at least 10 years, 
showing that clinical improvements are not just transient effects.9 While effective 
interventions may have a significant upfront investment, research using a simulation 
model projects that a nationwide prevention program would break even in 14 years and 
within 25 years, it would prevent or delay 885,000 cases of diabetes in US, producing a 
cost savings of $5.7 billion.10 
While their study provides an informative perspective on the internal validity of 
targeted interventions, less evidence exists on similar interventions performed in real-
world settings. In a study evaluating MOVE!, a weight management program from the 
Department of Veteran Affairs (VA), results showed a significant difference between the 




may prevent future weight gain.11 However, later study revealed low participation among 
eligible veterans and low estimates of weight loss when translating their earlier successes 
into a program that used provider-based referrals.12 Other Diabetes Prevention Program 
(DPP) translational efforts have piloted programs that demonstrate high attendance and 
low attrition when invited by a trusted health professional,13 effective weight loss when 
delivered by trained diabetes educators,14,15 and program sustainability when 
implemented within a community setting.7,16-18 Most studies using the RE-AIM 
framework have largely focused on the reach and effectiveness of interventions and 
rarely report the level of operational adoption and implementation in their research 
evaluations.19,20  
In early 2013, Intermountain Healthcare (IH) began work to identify the 
population at-risk for diabetes; institute an expert clinical development team to create a 
care process for the identification and management of patients with preDM; analyze 
current organizational health promotion and disease prevention infrastructure; and to 
create an education and referral process for patients identified with preDM. Based on a 
modified form of the National Diabetes Prevention Program (NDPP),6 the IH Diabetes 
Prevention Program (DPP) uniquely identifies patients with preDM and includes three 
different options for participation: a two-hour introduction group class, individualized 
nutritional counseling, or an intensive lifestyle intervention. 
Only a few health systems in the nation have identified those with preDM and 
intervened using evidenced-based programs for diabetes prevention. Little is known 
about diabetes prevention in regards to: the proportion or characteristics of eligible 




level of organizational diffusion among providers/clinics, and the fidelity to the program 
as it was deployed. The purpose of this study was to evaluate the reach, effectiveness, 
adoption, and implementation of the IH DPP deployed within a large, integrative 
delivery system among patients identified with preDM.  
Methods 
We conducted an evaluation of the DPP program using the RE-AIM framework 
(reach, effectiveness, adoption, implementation, maintenance) for organizing our 
analysis, results, and interpretation to focus on all framework dimensions except for 
maintenance.21-23 This framework emphasizes the need to evaluate health interventions 
beyond efficacy and effectiveness to include multiple criteria to better identify effect and 
transferability in a general population.24,25 
Intermountain Healthcare’s Diabetes Prevention Program 
In early 2013, within an organizational culture of rapid cycle quality 
improvement, the Primary Care Clinical Program began work on the creation of a 
defined Diabetes Prevention Program to deploy within primary care clinics at IH. As 
described elsewhere,26 this program identified patients who meet criteria for preDM 
(HbA1c 5.7-6.49% or Fasting Plasma Glucose 100-125mg/dL) for clinicians, provides an 
introductory class focused on awareness and goal setting for people with preDM, and 
leverages existing wellness initiatives for intensive lifestyle and behavior change 
education that have demonstrated effectiveness in the peer-reviewed literature.26 Briefly, 
the DPP is comprised of three different pathways to participate: (a) an introductory, two-
hour group class (Prediabetes 101); (b) individual, nutrition counseling sessions (Medical 




12 class periods within a 6-month period (Weigh to Health, or W2H). Patients can enroll 
in any or all of the differing pathways that make up the DPP (see Figure 3.1). 
Feasibility studies were conducted in five clinics between August 2013 and 
December 2013 to test the deployment of the Prediabetes 101 class. MNT and W2H 
were already in existence operationally throughout the system and were included as 
additional education pathways for DPP participants in August 2013. On the basis of the 
lessons learned during this testing, the DPP workgroup: revised the invitation process to 
participate by recommending an in-person invitation at the next PCP office visit rather 
than calling prospective patients; created distinct roles and responsibilities for the clinical 
and DPP teams; standardized the referral process and DPP documentation for all 
pathways in the electronic medical record; and engaged providers and clinical staff by 
performing regional trainings and clinical in-services for all impacted clinicians. IH 
medical and operational leadership issued a formal statement in January 2014 requiring 
that the Prediabetes 101 class would be free of charge to all patients and would be used 
as a patient engagement tool across the IH system. Medical Nutrition Therapy (MNT) 
and Weigh to Health (W2H) continued to require insurance coverage to be approved on a 
patient by patient basis. Full deployment throughout the IH delivery system of the 
Prediabetes 101 class occurred in January 2014. 
Data Sources 
In addition to routine clinical, administrative, and financial information about 
individual encounters, IH’s Enterprise Data Warehouse (EDW) was queried for all data 
on patient demographics (age, sex, race/ethnicity and insurance status) and clinical 




cohort included the proportion of patients with chronic conditions prior to study 
enrollment including: depression, coronary heart disease, congestive heart failure, atrial 
fibrillation, and high blood pressure. Criteria for chronic conditions are different for each 
condition; however, they are based on diagnosis codes and encounter data, and approved 
by an internal expert committee of practicing providers (see Table 2.2). The duration of 
preDM diagnosis was estimated based on the first documentation of laboratory values 
within the EDW system. Medication use was collected at time of study enrollment (anti-
hypertensive, atypical-neuroleptics, metformin, and statins). The institutional review 
board at Intermountain Healthcare approved this study. 
Study Participants 
A source population of adult patients (aged 18-75 years) who met criteria for 
preDM within the last 3 years was queried through IH’s EDW for each clinic. Patients 
were attributed to a primary care provider who provided the plurality of qualifying 
services (Current Procedural Terminology codes for outpatient visit, preventive medicine 
visit or wellness visit: 9920x, 9921x, 99385-87, 99395-97, G0101, G0402, G0438) in a 
given calendar year with most recent service breaking any ties. Patient-level data were 
distributed to the providers and clinic support staff so patients could be identified prior to 
arriving for their appointments. Patients were excluded for study if they had been 
diagnosed with diabetes prior or within 2 months of enrollment, had a known death 
within the study period, or ever had weight loss surgery. Patients who attended a 
Prediabetes 101 introductory class, MNT, or W2H between August 2013 and July 2014 
were considered as the DPP participant group. Patients who were eligible, or had the 




not participate, were considered as the control group. 
Assessment and Statistical Analyses of Reach  
Reach was defined by the rate of participation in those that enrolled in the DPP 
(numerator) compared to those that were eligible to participate in the DPP 
(denominator). Due to possible DPP implementation variation, data was stratified by IH 
region. Representativeness was based on comparisons of participants to nonparticipants 
for key demographic and health-related characteristics. To determine the independent 
associations between DPP participation and patient characteristics, multivariable logistic 
regression modeling was utilized.  
Assessment and Statistical Analyses of Effectiveness 
To assess the effectiveness dimension, unpublished results from a recent 
comparative analysis were reported to determine the association of 5% weight loss and 
the incidence of T2DM among participants and nonparticipants. The results and the 
approach have been described in detail elsewhere.26 Briefly, to determine which patients 
achieved a 5% weight loss, baseline weight was collected within 12 months of study 
enrollment and follow-up weight was collected within 5-7 months after enrollment. 
Change scores were calculated and a binary outcome of yes/no was computed if patients 
achieved a 5% weight loss from baseline. Incident diagnosis of T2DM (yes/no) was 
defined by the National Committee for Quality Assurance (NCQA) through the 
Healthcare Effectiveness Data and Information Set (HEDIS) specifications.27,28 These 
specifications require only one of the following to be met along with a diagnosis code of 
diabetes (ICD-9 code: 250): (a) two outpatient encounters on different dates of service; 




who were dispensed insulin or hypoglycemic/anti-hyperglycemics on an ambulatory 
basis. 
Conditional logistic regression modeling was utilized to obtain summary 
measures of relative risk for the study groups. Odds ratios were generated after 
adjustment for baseline differences including demographic and clinical characteristics 
that are well known to affect the ability to achieve the 5% weight loss. Similarly, this 
method was used to determine the incidence of T2DM among groups. Difference-in-
difference modeling was used to measure the association and magnitude measurement of 
weight change from baseline to follow-up. 
Assessment of Other RE-AIM Dimensions 
To assess adoption, we calculated the number of providers and clinics that 
implemented the DPP in the first year that it was deployed. The range of patients referred 
per provider was also reported. To evaluate implementation, we used a proxy measure of 
adherence or fidelity to the DPP flow process. We assessed the average number of 
encounters per patient by each DPP pathway and the proportion of patients who only had 
only 1 encounter within the DPP. The proportion of patients who enrolled in the W2H 
pathway was assessed for completeness (≥12 encounters).  
Results 
Reach 
17,142 people met the criteria for preDM during the study period (Figure 4.1). 
6,862 were eligible because they met study criteria, had an office visit with their 
provider, and had the opportunity to be invited. 8.4% patients participated (n=573) with 









W2H (patients could participate in any of all of the different DPP pathways, and thus the 
proportion among the group does not add up to 100%). Only 63 patients participated in 
more than one DPP pathway, with all of them participating in the Prediabetes 101 and 
MNT classes combined. The DPP participation rate was greatest for regions 2, 5, and 6. 
After adjusting for all factors listed in Table 4.1, the following characteristics 
were associated with an increased likelihood of participation: female sex, aged >70 
years, overweight BMI category, depression, and those prescribed metformin. Likelihood 
of participation was lower in patients with 5-9 years (referent <5years) duration of 
preDM diagnosis. Additional analyses were completed to adjust for possible clinic 
implementation variation using mixed-effects logistic modeling, which confirmed that 
female sex, and those prescribed metformin were more likely to participate (Table 4.2).  
Effectiveness 
As documented in Figure 4.2, patients in the DPP group were 70% more likely to 
achieve a 5% weight loss as compared to the control group (OR 1.70; 95%CI 1.29, 2.25; 
p<0.001) after adjustment for possible confounders. DPP patients were also less likely to 
have an incident diagnosis of T2DM during the study period (OR 0.49; 95%CI 0.28, 
0.86; p=0.012). After comparing the change in weight over time, DPP participation 
showed a trend toward significance with a greater reduction in weight when compared to 
the no-DPP group (ß= -1.36; 95%CI -2.76, 0.05; p=0.058). 
Adoption 
All measures related to the adoption dimension are documented in Table 4.3. Of 
the 8 regions within the IH system, the DPP was implemented in 7. One region was 




Table 4.1. Measurement of Reach: Characteristics and Associations of Patients Who 
Participated in the Diabetes Prevention Program 
Variables #pts 
DPP participants                                               
n =  573 
Nonparticipants              





M ± SD 
or % n 
M ± SD or 
% OR (95% CI) 
Demographics 
Age categories, %             
18-29 174 19 3.32 155 2.47 --- 
30-39 506 39 6.81 467 7.44 0.69 (0.40, 1.17) 
40-49 982 76 13.36 906 14.42 0.78 (0.44, 1.37) 
50-59 1916 165 28.81 1,751 27.88 0.91 (0.53, 1.56) 
60-69 2357 151 26.35 2,206 35.12 0.70 (0.40, 1.21) 
≥ 70 919 123 21.47 796 12.67 1.75 (1.08, 2.83)* 
Gender, %       
Male 3070 212 37.12 2,858 45.44 --- 
Female 3787 356 62.88 3,431 54.56 1.43 (1.09, 1.88)* 
Race/ethnicity       
White 5947 506 88.43 5,441 86.52 --- 
Hispanic 575 44 7.64 531 8.44 0.73 (0.39, 1.35) 
Black 57 4 0.66 53 0.84 0.80 (0.27, 2.35) 
Asian 145 10 1.75 135 2.15 0.98 (0.70, 1.38) 
Other 138 9 1.53 129 2.05 0.72 (0.46, 1.14) 
Insurance       
Commercial 3967 294 51.31 3,673 58.40 --- 
Medicare 2208 194 33.84 2,014 32.02 0.92 (0.77, 1.09) 
Medicaid 272 21 3.71 251 3.99 0.84 (0.51, 1.38) 
Uninsured 415 64 11.14 351 5.58 2.21 (0.85, 5.74) 
Clinical Characteristics 
Prediabetes duration, %       
<5 years 5389 458 79.91 4,931 78.41 --- 
5-9 years 1303 100 17.47 1,203 19.13 0.71 (0.56, 0.92)* 
>10 years 170 15 2.62 155 2.46 0.86 (0.49, 1.49) 
Chronic Conditions, %       
Depression 2808 272 47.38 2,536 40.32 1.15 (1.03, 1.28)* 
Coronary Heart Disease 1234 114 19.87 1,120 17.81 1.13 (0.76, 1.70) 
Heart Failure 516 51 8.95 465 7.39 0.93 (0.67, 1.29) 
Atrial Fibrillation 416 45 7.86 371 5.90 1.28 (0.91, 1.81) 
High Blood Pressure 3908 336 5873 3,572 56.80 1.12 (0.92, 1.35) 
Medication class, %       
Anti-hypertensive 3322 274 47.82 3,048 48.47 0.81 (0.54, 1.21) 
Anti-neurolyptics 576 55 9.61 521 8.28 1.02 (0.81, 1.29) 
Metformin 1110 124 21.62 986 15.68 1.36 (1.01, 1.87)* 
Statin 3497 304 53.06 3,193 50.77 0.97 (0.86, 1.11) 
BMI class at baseline, %       
Underweight 40 2 0.38 38 0.63 0.81 (0.26, 2.49) 
Normal 686 38 7.11 648 10.67 --- 
Overweight 1679 130 24.83 1,549 25.51 1.39 (1.02, 1.89)* 
Obese 4193 355 67.63 3,838 63.20 1.21 (0.68, 2.13) 





Table 4.2. Mixed-Effects Logistic Regression Modeling for Diabetes Prevention 
Program Participation 
Variables #preDM pts 
#DPP 
participants OR (95%CI) p 
     
Demographics  
Age categories         
18-29 174 19 --- --- 
30-39 506 39 0.67 (0.36, 1.24) 0.21 
40-49 982 76 0.79 (0.44, 1.40) 0.42 
50-59 1916 165 0.85 (0.49, 1.49) 0.57 
60-69 2357 151 0.67 (0.37, 1.21) 0.19 
≥ 70 919 123 1.62 (0.85, 3.10) 0.14 
Gender     
Male 3070 212 --- --- 
Female 3787 356 1.41 (1.15, 1.74) 0.001 
Race/ethnicity     
White 5947 506 --- --- 
Hispanic 575 44 0.93 (0.64, 1.34) 0.68 
Black 57 4 0.57 (0.19, 1.77) 0.34 
Asian 145 10 1.22 (0.61, 2.46) 0.57 
Other 138 9 0.74 (0.35, 1.58) 0.44 
Insurance     
Commercial 3967 294 --- --- 
Medicare 2208 194 0.86 (0.65, 1.14) 0.29 
Medicaid 272 21 0.77 (0.45, 1.29) 0.32 
Uninsured 415 64 1.47 (0.97, 2.24) 0.07 
Clinical Characteristics 
Prediabetes duration     
<5 years 5389 458 --- --- 
5-9 years 1303 100 0.71 (0.55, 0.92) 0.01 
>10 years 170 15 0.96 (0.53, 1.75) 0.90 
Chronic Conditions     
Depression 2808 272 1.13 (0.93, 1.39) 0.23 
Coronary Heart Disease 1234 114 1.02 (0.79, 1.33) 0.86 
Heart Failure 516 51 0.93 (0.63, 1.36) 0.70 
Atrial Fibrillation 416 45 1.30 (0.89, 1.89) 0.18 
High Blood Pressure 3908 336 1.15 (0.89, 1.47) 0.28 
Medication class     
Anti-hypertensive 3322 274 0.77 (0.60, 0.99) 0.04 
Anti-neurolyptics 576 55 0.99 (0.71, 1.41) 0.99 
Metformin 1110 124 1.32 (1.04, 1.68) 0.02 
Statin 3497 304 1.03 (0.84, 1.26) 0.79 
BMI class at baseline     
Underweight 40 2 0.61 (0.13, 2.92) 0.54 
Normal 686 38 --- --- 
Overweight 1679 130 1.37 (0.94, 1.99) 0.09 
Obese 4193 355 1.17 (0.79, 1.75) 0.43 
Clinic Characteristics 
# of paneled patients per clinic 6,862 573 1.00 (0.99, 1.00) 0.74 





Table 4.2. Continued 
Variables #preDM pts 
#DPP 
participants OR (95%CI) p 
     
Urban location of clinic     
No 1,276 118 --- --- 
Yes 5,013 455 1.24 (0.56, 2.78) 0.60 
Level of Medical Home Implementation     
None 1,083 147 --- --- 
Planning 449 27 0.57 (0.20, 1.63) 0.29 
Adoption 1,733 115 0.48 (0.23, 1.01) 0.05 
Routinized 3,024 284 0.59 (0.36, 0.98) 0.04 
     






Figure 4.2. Measurement of Effectiveness: Association among Diabetes Prevention 
Program Participation and (a) Achievement of 5% Weight Loss and (b) 
Incident Diagnosis of Type II Diabetes Mellitus. *p<0.01, adjusted for 
age, female sex, race category (White, Asian, Black, Hispanic, or 
other/unknown), insurance plan at enrollment (Commercial, Medicare, 
Medicaid, or Uninsured/Self-pay), duration of prediabetes diagnosis (<5 
years, 5-9 years, or ≥10 years), prevalence of chronic conditions 
(depression, coronary artery disease, heart failure, atrial fibrillation, high 
blood pressure), prescribed medication at enrollment (by drug class: anti-






Table 4.3. Measures of Adoption and Implementation: Summary Results of 
Organizational Diffusion and the Fidelity to Implementation of the Program 
Measures 
Intermountain Healthcare’s Geographical Regions 
1 2 3 4 5 6 7 Total 
Adoption Dimension 
Eligible preDM patients, n 603 1,236 1,205 944 791 597 1,486 6,862 
































DPP referring providers, n  15 44 21 19 22 22 31 174 
Range of patients referred 
per provider 
1-5 1-32 1-5 1-4 1-12 1-14 1-16 1-32 
Implementation Dimension 
No. of DPP counseling 
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counseling challenging and deferred participation during the first 12 months of the 
program. Within this primary care led intervention, 174 providers at 53 clinics referred 
patients to the DPP. The number of patients a provider referred for enrollment ranged 
from 1 to 32 and there was distinct variation among the differing regions on how many 
patients participated. 
Implementation 
As documented in Table 4.3, the mean number of DPP counseling encounters 
during follow-up was 2.3 and varied among regions (1-16). 66% of participants had only 
a single DPP counseling encounter (range across regions 51% to 85%), while for those 
that participated in W2H, roughly 54% had ≥ 12 encounters (range among regions 25% 
to 78%).  
Discussion 
Overall, the first year results from the IH DPP demonstrated encouraging 
potential for translating DPP-based interventions into primary care clinics within our 
large integrated, healthcare delivery system. While this study demonstrated that only a 
small proportion (8.4%) of patients with preDM participated in the program, for those 
that did participate, there was a significant association with achieving a 5% weight loss 
and reducing the incidence of T2DM when they were compared to a group who did not 
participate. Several patient characteristics emerged, such as older age, female sex, 
prevalent depression diagnosis, being overweight, and prescribed metformin, that were 
associated with a greater likelihood of participation. Medical and operational leadership 
supported this program, with broad adoption by clinics and providers across the IH 




referred less than 5 patients), several providers emerged as clinical champions of the 
program. In terms of implementation fidelity, few patients participated in more than one 
intervention option and the majority received only one encounter during the program.  
Results from this study support research from other DPP-based interventions 
deployed within comparable delivery systems such as Kaiser Permaneante Colorado20 
and the Department of Veteran Affairs (VA).29,30 Preliminary results from a national 
model of diabetes prevention linking health insurers and community programs suggest 
that “large-scale prevention efforts can be effective, scalable and sustainable with 
collaboration, health information technology, community-based delivery of evidence-
based interventions, and novel payment structures.” 31 Further efforts to understand the 
role that technology will play in delivering online lifestyle counseling may offer 
additional solutions for the future to address the obesity and diabetes epidemics.32 
Previous studies have laid the foundation for translating diabetes prevention into 
care delivery. However, our study builds upon these results by demonstrating broad 
support by organizational leadership and providers for enrolling patients in the program, 
while revealing promising effectiveness of the intervention amidst modest fidelity to the 
program as originally intended. Distinct patient characteristics such as female sex, older 
versus younger age, metformin, and categorized as overweight all had an increased 
likelihood of association with participation. A potentially unique finding from this study 
suggested that patients diagnosed with depression were more likely to participate as 
compared with those without the diagnosis. This may be attributed to high functioning, 
multidisciplinary teams which were able to identify patients with mental health disease 




participate in the program.  
Another unique finding suggested that there was broad adoption by providers and 
leadership across the system; however, there was distinct variability in the 
implementation or fidelity to the program across regions. Some regions supported 
implementation of the Prediabetes 101 class while others were more apt to refer patients 
to intensive lifestyle interventions, suggesting that providers or patients may inherently 
gravitate towards counseling that best fits individual needs. Among all regions, when a 
clinical champion was identified, we observed greater adoption and referral to all 
pathways within the IH DPP program. All findings warrant further validation and 
longitudinal study. 
Limitations 
Patients were not randomly assigned to participate in the intervention and 
therefore, motivation to participate or increased readiness to change behavior may 
explain associations in participation or the weight loss differences observed. This 
evaluation was performed within a short period of time after enrollment and further 
longitudinal study is needed to determine the sustainability of its impact over a 
prolonged period of time. While the methodology used in this study attempted to account 
for variation in reach and adoption of the program across the IH clinics where the 
patients received care, it might not account for all variation in practice which could affect 
the observed results.  
Study groups found within this study were carefully selected based on the 
definitions found within the literature; however, there is always a possibility that data 




who consider their obstetrician or gynecologist as the provider who delivers their care 
primarily were not studied in this analysis and may warrant further study. Patients with 
prevalent T2DM diagnosis were excluded, yet there remains a possibility that their 
diagnosis was not identified due to the definition criteria or care that occurred outside of 
the IH system. 
Findings from this study may not be generalizable to populations outside of IH 
because of differences in patient characteristics, local implementation, and resources 
allocated to this program. Information was not available on weight loss activities outside 
of the IH DPP program which potentially could differ between participants and 
nonparticipants. Social determinants of health such as where the patient was born, their 
current living conditions, and education and income level have also been associated with 
health outcomes, but were not available for study. Finally, we were limited in our ability 
to assess all dimensions of the RE-AIM framework, including direct measures of 
implementation and maintenance of the program.  
Conclusions 
DPP-based lifestyle interventions deployed within IH’s delivery system 
demonstrated moderate effectiveness in the short-term, yet the proportion of patients 
who were eligible to enroll was low. Broad adoption across regions by providers and 
leadership revealed organizational buy-in, while demonstrating that much of the clinical 
effect was seen when patients participated in an intervention that was far less resource 
intensive as compared to the landmark studies by the National Diabetes Prevention 
Program. As demonstrated by the large population and low reach of participation that 




more of our affected populations and scale these established interventions for those at 
risk for disease. 
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The prevalence and costs associated with type II diabetes (T2DM) not only 
challenge the financial integrity of our healthcare system, but present a clinical epidemic 
that has made preventing this disease a public health priority. The ability to recognize 
those who are at-risk for T2DM, by identifying patients with prediabetes (preDM), 
represents an opportunity to reduce both the incidence and cost of disease over time. 
Several published studies have established the utility of screening protocols and the 
effectiveness of basic healthy lifestyle interventions within a preDM population, yet very 
few healthcare delivery systems target these patients with such an intervention. 
Compared to the amount of research demonstrating the efficacy of such interventions, 
relatively few studies have assessed the external validity of implementing a Diabetes 
Prevention Program (DPP) and the impact in the short term. This body of research 
indicated that: 
1. Confirmed and unconfirmed preDM is strongly associated with the 
development of T2DM as compared to patients with only risk factors for 
disease. Furthermore, increasing age in addition to preDM increases a 
person’s chance of developing T2DM, confirming the recent screening 




2. Adaptation of DPP-based lifestyle interventions deployed within primary care 
clinics demonstrated a significant improvement in achieving a 5% weight loss 
and reduced the incidence of T2DM among participants when compared to 
nonenrollees. 
3. Intermountain Healthcare’s DPP demonstrated significant effectiveness in the 
short-term, yet the proportion of patients who enrolled was low. Additionally, 
broad adoption by providers and operational leadership revealed 
organizational buy-in, while demonstrating much of the clinical effect was 
seen when patients participated in an intervention that was far less resource 
intensive as compared to landmark studies by the National Diabetes 
Prevention Program. 
The results of this dissertation suggest that diabetes prevention using known 
lifestyle interventions delivered within primary care practices is feasible and an effective 
intervention to use in patients with confirmed preDM.  Future directions for study 
include: further longitudinal evaluation to determine the sustained impact of the DPP 
program; extending invitation to other eligible populations (such as patients with 
unconfirmed preDM) to participate in the DPP intervention; leveraging technology to 
reach more of the affected population and scale evidence-based interventions; and 
including other stakeholders (i.e., patients, families, and insurers) within the 
implementation process to garner further refinement of the program. 
 
